T1 invasive lung adenocarcinoma: Thin-section CT solid score and histological periostin expression predict tumor recurrence.
lung adenocarcinoma
multidetector computed tomography
periostin protein
prognosis
solid component
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
15
03
2021
accepted:
12
08
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
Adenocarcinoma is the most common histological type of non-small cell lung cancer (NSCLC), and various biomarkers for predicting its prognosis after surgical resection have been suggested, particularly in early-stage lung adenocarcinoma. Periostin (also referred to as POSTN, PN or osteoblast-specific factor) is an extracellular matrix protein, the expression of which is associated with tumor invasiveness in patients with NSCLC. In the present study, the novel approach, in which the thin-section CT findings prior to surgical resection and periostin expression of resected specimens were analyzed in combination, was undertaken to assess whether the findings could be a biomarker for predicting the outcomes following resection of T1 invasive lung adenocarcinoma. A total of 73 patients who underwent surgical resection between January 2000 and December 2009 were enrolled. A total of seven parameters were assessed in the thin-section CT scans: i) Contour; ii) part-solid ground-glass nodule or solid nodule; iii) percentage of solid component (the CT solid score); iv) presence of air-bronchogram and/or bubble-like lucencies; v) number of involved vessels; vi) shape linear strands between the nodule and the visceral pleura; and vii) number of linear strands between the nodule and the visceral pleura. Two chest radiologists independently assessed the parameters. Periostin expression was evaluated on the basis of the strength and extent of staining. Univariate and multivariate analyses were subsequently performed using the Cox proportional hazards model. There was a substantial to almost perfect agreement between the two observers with regard to classification of the seven thin-section CT parameters (κ=0.64-0.85). In the univariate analysis, a CT solid score >80%, pathological lymphatic invasion, tumor and lymph node status and high periostin expression were significantly associated with recurrence (all P<0.05). Multivariate analysis demonstrated that a CT solid score >80% and high periostin expression were risk factors for recurrence (P=0.002 and P=0.011, respectively). The cumulative recurrence rates among the three groups (both negative, CT solid score >80% or high periostin expression, or both positive) were significantly different (log-rank test, P<0.001). Although the solid component is already known to be a major predictor of outcome in lung adenocarcinomas according to previous studies, the combined analysis of CT solid score and periostin expression might predict the likelihood of tumor recurrence more precisely.
Identifiants
pubmed: 34650799
doi: 10.3892/mco.2021.2391
pii: MCO-0-0-02391
pmc: PMC8506662
doi:
Types de publication
Journal Article
Langues
eng
Pagination
228Informations de copyright
Copyright: © Iwamoto et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Lett. 2001 Oct 22;172(1):37-42
pubmed: 11595127
Oncol Lett. 2013 Dec;6(6):1595-1603
pubmed: 24273600
J Thorac Oncol. 2017 Jun;12(6):954-962
pubmed: 28257958
Eur J Cardiothorac Surg. 2013 May;43(5):915-8
pubmed: 23024235
Radiology. 2017 Nov;285(2):584-600
pubmed: 28650738
Transl Lung Cancer Res. 2017 Feb;6(1):14-22
pubmed: 28331820
Cancer Res. 2006 Jul 15;66(14):6928-35
pubmed: 16849536
Mod Pathol. 2011 May;24(5):653-64
pubmed: 21252858
Cell Mol Life Sci. 2014 Apr;71(7):1279-88
pubmed: 24146092
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Histol Histopathol. 2007 Oct;22(10):1167-74
pubmed: 17616943
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
Am J Surg Pathol. 2014 Apr;38(4):448-60
pubmed: 24472852
J Thorac Oncol. 2017 Aug;12(8):1288-1298
pubmed: 28576745
Cancer. 2014 Sep 15;120(18):2883-92
pubmed: 25113306
Kurume Med J. 2018 Feb 26;64(1.2):13-20
pubmed: 29176296
Eur Respir J. 2011 May;37(5):1119-27
pubmed: 21177844
Cancer. 2001 Aug 15;92(4):843-8
pubmed: 11550156
J Thorac Cardiovasc Surg. 2013 Jul;146(1):24-30
pubmed: 23398645
Mod Pathol. 2008 Aug;21(8):1044-53
pubmed: 18487994
Biochem J. 1993 Aug 15;294 ( Pt 1):271-8
pubmed: 8363580
Radiology. 1991 May;179(2):469-76
pubmed: 2014294
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1318-23
pubmed: 26228108
Radiology. 2014 Oct;273(1):285-93
pubmed: 25102296
AJR Am J Roentgenol. 2001 Dec;177(6):1417-22
pubmed: 11717098
Radiology. 2012 Sep;264(3):884-93
pubmed: 22829686
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489
Cell Mol Life Sci. 2009 Jul;66(14):2219-30
pubmed: 19308325
Interact Cardiovasc Thorac Surg. 2016 Jun;22(6):831-8
pubmed: 26920725
Radiology. 2003 Aug;228(2):303-8
pubmed: 12819342
J Cardiothorac Surg. 2018 Jan 17;13(1):9
pubmed: 29343293
Oncol Rep. 2011 May;25(5):1211-6
pubmed: 21347516